{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:54:33Z","timestamp":1780066473032,"version":"3.54.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.leukres.2009.02.006","type":"journal-article","created":{"date-parts":[[2009,3,27]],"date-time":"2009-03-27T08:43:36Z","timestamp":1238143416000},"page":"1233-1242","source":"Crossref","is-referenced-by-count":75,"title":["Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy"],"prefix":"10.1016","volume":"33","author":[{"given":"Daniel A.","family":"Vallera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Sicheneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Panoskaltsis-Mortari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Taras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.02.006_bib1","first-page":"937","article-title":"Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia","volume":"10","author":"List","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.02.006_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/14712598.2.8.785","article-title":"Recombinant fusion toxins for cancer treatment","volume":"2","author":"Kreitman","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.leukres.2009.02.006_bib3","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood.V90.6.2364","article-title":"Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization","volume":"90","author":"Goulet","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.02.006_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V88.4.1188.bloodjournal8841188","article-title":"A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma","volume":"88","author":"Stone","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.02.006_bib5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.1995.517","article-title":"Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours","volume":"72","author":"Flavell","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2009.02.006_bib6","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","article-title":"CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest","volume":"83","author":"Ghetie","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.02.006_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.163.2.347","article-title":"Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia","volume":"163","author":"Uckun","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2009.02.006_bib8","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.02.006_bib9","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.02.006_bib10","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1158\/1078-0432.CCR-04-2290","article-title":"A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia\/lymphoma","volume":"11","author":"Vallera","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.leu.2402790","article-title":"Treatment of SCID\/human B cell precursor all with anti-CD19 and anti-CD22 immunotoxins","volume":"17","author":"Herrera","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.02.006_bib12","first-page":"1302","article-title":"A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma","volume":"6","author":"Messmann","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib13","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1158\/1078-0432.CCR-06-2454","article-title":"Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv","volume":"13","author":"Stish","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/gut.2007.137802","article-title":"Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model","volume":"57","author":"Vallera","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.leukres.2009.02.006_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11060-007-9499-8","article-title":"Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model","volume":"87","author":"Stish","year":"2008","journal-title":"J Neurooncol"},{"key":"10.1016\/j.leukres.2009.02.006_bib16","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/1078-0432.CCR-07-0938","article-title":"A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer","volume":"13","author":"Stish","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/protein\/gzh023","article-title":"A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model","volume":"17","author":"Todhunter","year":"2004","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.leukres.2009.02.006_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(78)90099-5","article-title":"One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell","volume":"15","author":"Yamaizumi","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2009.02.006_bib19","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1016\/S0021-9258(19)38482-0","article-title":"Structure\/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells","volume":"265","author":"Williams","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2009.02.006_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/br.39.1.54-85.1975","article-title":"Diphtheria toxin: mode of action and structure","volume":"39","author":"Collier","year":"1975","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.leukres.2009.02.006_bib21","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1016\/S0021-9258(19)68883-6","article-title":"Diphtheria toxin. Site and configuration of ADP-ribosylation of diphthamide in elongation factor 2","volume":"256","author":"Oppenheimer","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2009.02.006_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0022-1759(96)00115-9","article-title":"Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry","volume":"196","author":"Kipriyanov","year":"1996","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.leukres.2009.02.006_bib23","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib24","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood.V86.7.2732.2732","article-title":"A murine cytokine toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells","volume":"86","author":"Chan","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.02.006_bib25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1074\/jbc.M409783200","article-title":"In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin","volume":"280","author":"Ho","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2009.02.006_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.leukres.2004.08.006","article-title":"Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice","volume":"29","author":"Vallera","year":"2005","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib27","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/blood.V88.6.2342.bloodjournal8862342","article-title":"Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor","volume":"88","author":"Vallera","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.02.006_bib28","first-page":"2837","article-title":"A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity","volume":"9","author":"Di Paolo","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib29","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1073\/pnas.89.13.5867","article-title":"Free in PMC Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin","volume":"89","author":"Batra","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2009.02.006_bib30","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/sj.onc.1206779","article-title":"Biologic and therapeutic role of HER2 in cancer","volume":"22","author":"Menard","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2009.02.006_bib31","first-page":"65","article-title":"Production of monoclonal antibodies for the diagnosis of minimal infiltration of leukemic cells into the bone marrow. B cell specific antibodies","volume":"67","author":"Dorken","year":"1983","journal-title":"Verh Dtsch Gs Path"},{"key":"10.1016\/j.leukres.2009.02.006_bib32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ijc.2910210207","article-title":"Two E-rosette-forming lymphoid cell lines","volume":"21","author":"Morikawa","year":"1978","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2009.02.006_bib33","first-page":"1300","article-title":"Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines","volume":"28","author":"Klein","year":"1968","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(64)92345-1","article-title":"Cytology of Burkitt's Tumor","volume":"1","author":"Pulvertaft","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2009.02.006_bib35","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","article-title":"Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity","volume":"68","author":"Du","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2009.02.006_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"key":"10.1016\/j.leukres.2009.02.006_bib37","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/sj.gt.3302557","article-title":"Protein toxins: intracellular trafficking for targeted therapy","volume":"12","author":"Johannes","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.leukres.2009.02.006_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0008-8749(86)90321-7","article-title":"Evaluation of ricin A-chain immunotoxins directed against human T cells","volume":"102","author":"Press","year":"1986","journal-title":"Cell Immunol"},{"key":"10.1016\/j.leukres.2009.02.006_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0192-0561(92)90176-L","article-title":"The macroscopic and microscopic pharmacology of monoclonal antibodies","volume":"14","author":"Weinstein","year":"1992","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.leukres.2009.02.006_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1097-0215(19990331)81:1<148::AID-IJC24>3.0.CO;2-L","article-title":"Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys","volume":"81","author":"Kreitman","year":"1999","journal-title":"Int J Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T17:38:53Z","timestamp":1633282733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609000630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0145212609000630"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.02.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}